Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clindamycin + triamcinolone acetonide is a compounded pharmaceutical preparation that combines two active ingredients with complementary actions. Clindamycin is a semi-synthetic lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome, thereby impeding assembly and translation processes. It is effective against susceptible anaerobic bacteria and certain Gram-positive organisms[5]. Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties, acting primarily through glucocorticoid receptor agonism to reduce inflammation and immune responses[4][8]. The combination has been used topically (e.g., nasal gel) for conditions such as rhinitis, sinusitis, allergic rhinitis, nasal polyps, and chronic rhinosinusitis where both antimicrobial action and reduction of inflammation are desired[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin + triamcinolone acetonide.